---
title: "Guardant Health (GH) Gets a Buy from Wells Fargo"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286044830.md"
description: "Wells Fargo analyst Brandon Couillard has maintained a Buy rating on Guardant Health (GH) with a price target of $125.00. Couillard, a 5-star analyst, has an average return of 15.6% and a success rate of 58.51%. Guardant Health also received a Buy rating from Guggenheim’s Subbu Nambi, while Evercore ISI maintained a Hold rating on May 8."
datetime: "2026-05-12T06:17:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286044830.md)
  - [en](https://longbridge.com/en/news/286044830.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286044830.md)
---

# Guardant Health (GH) Gets a Buy from Wells Fargo

Wells Fargo analyst Brandon Couillard maintained a Buy rating on Guardant Health on May 9 and set a price target of $125.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Couillard is a 5-star analyst with an average return of 15.6% and a 58.51% success rate. Couillard covers the Healthcare sector, focusing on stocks such as Guardant Health, Bio-Rad Laboratories, and Myriad Genetics.

In addition to Wells Fargo, Guardant Health also received a Buy from Guggenheim’s Subbu Nambi in a report issued yesterday. However, on May 8, Evercore ISI maintained a Hold rating on Guardant Health (NASDAQ: GH).

### Related Stocks

- [GH.US](https://longbridge.com/en/quote/GH.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IDNA.US](https://longbridge.com/en/quote/IDNA.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IHF.US](https://longbridge.com/en/quote/IHF.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [WFC.US](https://longbridge.com/en/quote/WFC.US.md)
- [BIO.US](https://longbridge.com/en/quote/BIO.US.md)
- [MYGN.US](https://longbridge.com/en/quote/MYGN.US.md)
- [EVR.US](https://longbridge.com/en/quote/EVR.US.md)
- [WFC-D.US](https://longbridge.com/en/quote/WFC-D.US.md)
- [WFC-L.US](https://longbridge.com/en/quote/WFC-L.US.md)
- [WFC-Y.US](https://longbridge.com/en/quote/WFC-Y.US.md)
- [WFC-C.US](https://longbridge.com/en/quote/WFC-C.US.md)
- [WFC-Z.US](https://longbridge.com/en/quote/WFC-Z.US.md)
- [WFC-A.US](https://longbridge.com/en/quote/WFC-A.US.md)
- [BIO.B.US](https://longbridge.com/en/quote/BIO.B.US.md)

## Related News & Research

- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Jefferies Sticks to Their Buy Rating for Dexcom (DXCM)](https://longbridge.com/en/news/286443716.md)
- [Analyst Reaffirms Buy on PAVmed, Citing Oncology Platform Momentum and Partnerships; Price Target Maintained at $16](https://longbridge.com/en/news/286945953.md)